Bayer (FRA:BAYN) has been assigned a €110.00 ($127.91) price objective by investment analysts at UBS Group in a research report issued on Tuesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target indicates a potential upside of 86.41% from the stock’s current price.
A number of other equities research analysts also recently commented on the company. Sanford C. Bernstein started coverage on Autohome in a research report on Thursday, June 27th. They issued an “outperform” rating and a $110.00 target price on the stock. Kepler Capital Markets set a €70.00 ($81.40) target price on Bayer and gave the company a “neutral” rating in a research report on Thursday, June 27th. Nord/LB restated a “neutral” rating on shares of Bayerische Motoren Werke in a research report on Tuesday, June 4th. Warburg Research set a €17.00 ($19.77) target price on Leoni and gave the company a “neutral” rating in a research report on Wednesday, May 15th. Finally, Deutsche Bank cut their price objective on Xilinx from $125.00 to $120.00 and set a “hold” rating on the stock in a report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company. Bayer currently has a consensus rating of “Hold” and an average price target of €80.63 ($93.76).
FRA:BAYN opened at €59.01 ($68.62) on Tuesday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98). The company has a fifty day simple moving average of €56.45.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: Earnings Per Share (EPS)
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.